Moringa is now too broad a noun to be useful. CDC's February moringa-capsule investigation involved an ended outbreak, older consumers, hospitalizations and extensively drug-resistant Salmonella. [1] FDA's companion page likewise treats the XDR moringa powder investigation as a specific product and resistance problem. [2]

Thursday's paper said FDA had reopened a moringa Salmonella investigation after new illnesses. Friday's service update separates that active shelf problem from the ended XDR one. CDC's current moringa page concerns different lots and a different recall lane. [3]

That distinction is the article. A consumer standing in a kitchen does not need a wellness argument about whether moringa is good or bad. She needs to know which bottle, which lot, which outbreak, which symptoms, and whether antibiotic resistance changes the risk.

MSM tends to compress recalls into brand lists. X will defend supplements or condemn the category. The paper should sort. If the current investigation and the ended XDR outbreak later converge through a supplier or facility, that will be news. Today, their difference is the useful fact.

Sorting is not less urgent than warning. It is how a warning becomes something a shopper can act on without emptying every shelf.

-- NORA WHITFIELD, Chicago